Many trials are studying the effects of tyrosine kinase inhibitors in this group of patients as consolidation therapy; for example, Osimertinib safety and efficacy are being assessed in a currently ongoing global phase 3 trial following concurrent or sequential chemoradiation in a patient with stage III (A/B/C) unresectable NSCLC and EGFR positive [19]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.